Provided by Tiger Trade Technology Pte. Ltd.

AI Healthcare

744.55
-26.8381-3.48%
Number of Gainers:1
Number of Losers:3
Number of Flat:- -
PE:- -
High:773.90
Open:771.53
Low:742.04
Close:771.39
Volume:27.41M
Turnover:732.77M
Market Cap:23.95B
Float Cap:18.32B

Loading ...

Tempus AI price target raised to $92 from $65 at Guggenheim

TIPRANKS
·
Yesterday

Tempus AI Says 13 Clinical Research Abstracts Win ESMO 2026 Presentation Slots

Reuters
·
Yesterday

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026

THOMSON REUTERS
·
Yesterday

Tempus AI Diagnostics CEO Thomas Edward Schoenherr Disposes of $873,885 in Common Shares

Reuters
·
Sep 30

Tempus AI Wins FDA Clearance for ECG-MR Tool to Flag Undiagnosed Mitral Regurgitation

Reuters
·
Sep 28

Tempus Receives FDA Clearance for Its Ecg-Mr AI Product Designed to Identify Undiagnosed Mitral Regurgitation

THOMSON REUTERS
·
Sep 28

ToolGen Raises KRW 19.5 Billion to Fund CRISPR Patent Battles and R&D

TIPRANKS
·
Sep 28

Snowflake, Palo Alto, Dell, GameStop, Crispr Insider Shock

TIPRANKS
·
Sep 26

Crispr Therapeutics General Counsel James R. Kasinger Disposes of Common Shares Worth $626,459.6

Reuters
·
Sep 25

Tempus AI CEO and Chairman Eric P. Lefkofsky Disposes of $17,868,777.62 in Class a Shares

Reuters
·
Sep 25

Tempus AI Inc Stock (TEM) Closed Up by 7.38% on Sep 24: What Investors Need To Know

TradingKey
·
Sep 25

tempus AI Inc Class A call volume above normal and directionally bullish

TIPRANKS
·
Sep 25

Editas slips amid pressure on gene-editing sector after Anthropic update

TIPRANKS
·
Sep 24

Claude discovers novel enzyme system with CRISPR-like repeats

TIPRANKS
·
Sep 24

Analysts Have Conflicting Sentiments on These Healthcare Companies: Tempus AI, Inc. Class A (TEM) and Avantor (AVTR)

TIPRANKS
·
Sep 22

Cathie Wood’s ARK Investment buys 103K shares of Beam Therapeutics today

TIPRANKS
·
Sep 22

Crispr Therapeutics Director Ali Behbahani Disposes of Common Shares Worth $780,649.24

Reuters
·
Sep 22

Recursion Licenses TxFM RNA Foundation Model to Tempus AI for Oncology Use in USD 12 Million Deal

Reuters
·
Sep 22

Tempus Extends Data Licensing Partnership with Recursion Through November 2029

Reuters
·
Sep 22

Tempus AI, Recursion Extend Data License, Amend Fee Structure

MT Newswires Live
·
Sep 21